Bellerophon Therapeutics Inc (BLPH):企業の財務・戦略的SWOT分析

◆英語タイトル:Bellerophon Therapeutics Inc (BLPH) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH512312FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD600 ⇒換算¥88,800見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥133,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Bellerophon Therapeutics Inc (Bellerophon Therapeutics), formerly Known as Bellerophon Therapeutics LLC is a clinical-stage biotherapeutics company that focuses on the development of therapies for the treatment of cardiopulmonary diseases. The company’s lead investigational cardiopulmonary product candidate, INOpulse, a combination drug-device therapy intended for the treatment of pulmonary hypertension associated with interstitial lung disease, pulmonary hypertension associated with sarcoidosis and pulmonary hypertension associated with chronic obstructive pulmonary disease. It develops INOpulse platform is based on its proprietary pulsatile nitric oxide delivery device. Bellerophon Therapeutics is headquartered in Warren, New Jersey, the US.

Bellerophon Therapeutics Inc Key Recent Developments

Mar 11,2021: Bellerophon Provides Clinical Program Update and Reports Fourth Quarter and Full-Year 2020 Financial Results
Mar 02,2021: Bellerophon to Present at the H.C. Wainwright Global Life Sciences Conference
Nov 05,2020: Bellerophon provides clinical program update and reports third quarter 2020 financial results
Aug 11,2020: Bellerophon appoints cardiopulmonary disease expert Wassim Fares, M.D., MSCR, as Chief Medical Officer
Aug 05,2020: Bellerophon provides clinical program update and reports second quarter 2020 financial results

This comprehensive SWOT profile of Bellerophon Therapeutics Inc provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Bellerophon Therapeutics Inc including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Bellerophon Therapeutics Inc – Key Information
Bellerophon Therapeutics Inc – Overview
Bellerophon Therapeutics Inc – Key Employees
Bellerophon Therapeutics Inc – Key Employee Biographies
Bellerophon Therapeutics Inc – Key Operational Heads
Bellerophon Therapeutics Inc – Major Products and Services
Bellerophon Therapeutics Inc – History
Bellerophon Therapeutics Inc – Company Statement
Bellerophon Therapeutics Inc – Locations And Subsidiaries
Bellerophon Therapeutics Inc
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Bellerophon Therapeutics Inc – Business Description
Bellerophon Therapeutics Inc – Corporate Strategy
Bellerophon Therapeutics Inc – SWOT Analysis
SWOT Analysis – Overview
Bellerophon Therapeutics Inc – Strengths
Bellerophon Therapeutics Inc – Weaknesses
Bellerophon Therapeutics Inc – Opportunities
Bellerophon Therapeutics Inc – Threats
Bellerophon Therapeutics Inc – Key Competitors

Section 3 – Company Financial Performance Charts

Bellerophon Therapeutics Inc – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Bellerophon Therapeutics Inc, Key Information
Bellerophon Therapeutics Inc, Key Ratios
Bellerophon Therapeutics Inc, Share Data
Bellerophon Therapeutics Inc, Major Products and Services
Bellerophon Therapeutics Inc, History
Bellerophon Therapeutics Inc, Key Employees
Bellerophon Therapeutics Inc, Key Employee Biographies
Bellerophon Therapeutics Inc, Key Operational Heads
Bellerophon Therapeutics Inc, Other Locations
Bellerophon Therapeutics Inc, Subsidiaries
Bellerophon Therapeutics Inc, Key Competitors
Bellerophon Therapeutics Inc, SWOT Analysis
Bellerophon Therapeutics Inc, Ratios based on current share price
Bellerophon Therapeutics Inc, Annual Ratios
Bellerophon Therapeutics Inc, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Bellerophon Therapeutics Inc (BLPH):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Barco NV (BAR):企業の財務・戦略的SWOT分析
    Barco NV (BAR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Arden Partners Plc (ARDN):企業の財務・戦略的SWOT分析
    Summary Arden Partners Plc (Arden) is a multi-service stockbroker that provides a range of financial services to corporate and institutional clients. The company offers research, distribution, execution and corporate finance services. Arden distribution services include providing unique trading thou …
  • Southern Research Institute:製薬・医療:M&Aディール及び事業提携情報
    Summary Southern Research Institute (Southern Research) is an independent, non-profit, and scientific research organization that conducts research in the areas of preclinical drug development, advanced engineering, drug discovery, environmental protection, and others. The organization offers life sc …
  • Tech Mahindra Limited:企業の戦略・SWOT・財務分析
    Tech Mahindra Limited - Strategy, SWOT and Corporate Finance Report Summary Tech Mahindra Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Pon Holdings B.V.:企業のM&A・事業提携・投資動向
    Pon Holdings B.V. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Pon Holdings B.V. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …
  • ImmunoCellular Therapeutics Ltd (IMUC)-医療機器分野:企業M&A・提携分析
    Summary ImmunoCellular Therapeutics Ltd (IMCU) is a clinical-stage biotechnology company which develops immune-based therapies for the treatment of various cancers. The product pipeline of the company includes active immunotherapies and patented monoclonal antibodies. IMCU’s immunotherapies product …
  • T7 Global Bhd (T7GLOBAL):石油・ガス:M&Aディール及び事業提携情報
    Summary T7 Global Bhd (T7 Global), formerly Tanjung Offshore Berhad, is an oil and gas company that offers gas generators and integrated services. The company's services include topside maintenance, engineering and procurement, installation and commissioning, initial engineering design layout, proje …
  • ZIL Ltd:企業の戦略・SWOT・財務分析
    ZIL Ltd - Strategy, SWOT and Corporate Finance Report Summary ZIL Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Rhino Resource Partners LP:企業の戦略・SWOT・財務情報
    Rhino Resource Partners LP - Strategy, SWOT and Corporate Finance Report Summary Rhino Resource Partners LP - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Metropolis Healthcare Ltd-医療機器分野:企業M&A・提携分析
    Summary Metropolis Healthcare Ltd (Metropolis Healthcare) is a healthcare service provider that provides pathology testing services. The center provides tests and test combinations, which ranges from routine screening tests to specialized molecular and genetic assays. It also specializes in clinical …
  • Arma Global Corporation:企業の戦略・SWOT・財務情報
    Arma Global Corporation - Strategy, SWOT and Corporate Finance Report Summary Arma Global Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Ricoh Imaging Co Ltd:企業の戦略的SWOT分析
    Ricoh Imaging Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Yuanta Financial Holding Co., Ltd.:戦略・SWOT・企業財務分析
    Yuanta Financial Holding Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Yuanta Financial Holding Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Global Alliance for TB Drug Development:製薬・医療:M&Aディール及び事業提携情報
    Summary Global Alliance for TB Drug Development (TB Alliance) is a non-profit organization that discovers and develops drugs to treat tuberculosis. The organization’s products include natural products, rifampin, pyrazinamide, isoniazid, macrokuds, ethambutol, and topoisomerase inhibitors. It offers …
  • Global Tungsten & Powders Corp.:企業の戦略・SWOT・財務分析
    Global Tungsten & Powders Corp. - Strategy, SWOT and Corporate Finance Report Summary Global Tungsten & Powders Corp. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • OGK-2 (OGKB):企業の財務・戦略的SWOT分析
    OGK-2 (OGKB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pote …
  • Lonza Group Ltd (LONN):製薬・医療:M&Aディール及び事業提携情報
    Summary Lonza Group Ltd (Lonza) is a biopharmaceutical company that manufactures and develops chemical and biological active pharmaceutical ingredients, and other products and services. The company offers active pharmaceutical ingredients, stem cell therapies, drinking water sanitizers, vitamin B co …
  • Shikoku Electric Power Co Inc (9507):企業の財務・戦略的SWOT分析
    Shikoku Electric Power Co Inc (9507) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • H. Lee Moffitt Cancer Center & Research Institute Inc-医療機器分野:企業M&A・提携分析
    Summary H. Lee Moffitt Cancer Center & Research Institute Inc (Moffitt) is a healthcare service provider that concentrates on the development of early stage translational research aimed at the rapid translation of scientific discoveries to benefit patient care. The center offers medical services suc …
  • Xenon Pharmaceuticals Inc (XENE):製薬・医療:M&Aディール及び事業提携情報
    Summary Xenon Pharmaceuticals Inc (Xenon), formerly Xenon Genetics Inc, is a biopharmaceutical company that discovers and develops therapeutics for patients suffering with neurological disorders. The company's pipeline products include XEN1101, XEN901, XEN007 and GDC-0310. It discovers various valid …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆